User profiles for AP Cope

Andrew Cope

Professor of Rheumatology, King's College London
Verified email at kcl.ac.uk
Cited by 15192

EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid …

…, C Gabay, AI Catrina, AP Cope… - Annals of the …, 2012 - ard.bmj.com
The Study Group for Risk Factors for Rheumatoid Arthritis was established by the EULAR
Standing Committee on Investigative Rheumatology to facilitate research into the preclinical …

[PDF][PDF] The central role of T cells in rheumatoid arthritis

AP Cope, H Schulze-Koops… - Clinical and experimental …, 2007 - researchgate.net
… For none of these three approaches is it presently clear how they might affect the function …
COPE AP: Studies of T-cell activation in chronic inflammation. Arthritis Res 2002; 4 (Suppl. 3…

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

…, S Norton, F Atzeni, M Galli, AP Cope… - …, 2019 - academic.oup.com
… Andrew P Cope , Andrew P Cope … Katie Bechman, Sujith Subesinghe, Sam Norton, Fabiola
Atzeni, Massimo Galli, Andrew P Cope, Kevin L Winthrop, James B Galloway, A systematic …

T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells

…, MA Cooper, M Arno, B Afzali, HJ Lachmann, AP Cope… - Science, 2016 - science.org
INTRODUCTION The inflammasomes and the complement system are traditionally viewed
as quintessential components of innate immunity required for the detection and elimination of …

Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases

AP Cope, D Gibbons, FM Brennan… - … : Official Journal of …, 1992 - Wiley Online Library
… Many biologic activities of TNFa appear to be involved in the pathogenesis of chronic
inflammation and arthritis. Thus, TNFa can induce resorption of cartilage and bone (1,2), …

[HTML][HTML] The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

…, D Baudry, MA Brown, AP Cope… - The Lancet …, 2021 - thelancet.com
Background Patients on therapeutic immunosuppressants for immune-mediated inflammatory
diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate …

[HTML][HTML] Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation

…, A Ersek, DF Baban, LM Williams, AP Cope… - PloS one, 2012 - journals.plos.org
A major therapeutic challenge is how to replace bone once it is lost. Bone loss is a characteristic
of chronic inflammatory and degenerative diseases such as rheumatoid arthritis and …

Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling

AP Cope, RS Liblau, XD Yang, M Congia… - The Journal of …, 1997 - rupress.org
… Indeed, repeated injections of adult female NOD mice with anti-TNF significantly increase
the incidence and severity of diabetes compared to control animals (Cope, AP, and HO …

[HTML][HTML] Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?

…, L Svensson, C Sanchez-Blanco, M Saini, AP Cope - FEBS letters, 2011 - Elsevier
… Our laboratory has also demonstrated the importance of reduced IL-2 production in this
model, in the context of skewed Th cell differentiation (Somenzi and Cope, unpublished data). …

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

…, K Benesova, TRDJ Radstake, AP Cope… - Annals of the …, 2021 - ard.bmj.com
Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the …